PJT Stock Analysis: PJT | NYSE
Capital Markets | NYSE, USA | Market Cap: 7.427m USD | 12M Return: 0.4% | US69343T1079 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 69.5M
EPS Trend: 98.9%
Qual. Beats: 1
Rev. Trend: 99.2%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
PJT Partners Inc. is a New York-based investment bank that provides strategic advisory, shareholder advisory, capital markets advisory, and restructuring services to corporations, financial sponsors, institutional investors, and governments worldwide. The firm was incorporated in 2014 and spun off from Blackstone in 2015, when it was renamed from Blackstone Advisory Inc. and subsequently listed on the NYSE in October 2015.
The companys advisory work spans mergers and acquisitions (including spin-offs, activism defense, contested M&A, joint ventures, and divestitures), debt and equity capital markets transactions such as IPOs and acquisition financings, and liability management and Chapter 11 restructurings. It also offers private fund advisory and fundraising services, as well as a dedicated geopolitical and policy advisory practice that supports corporate boards and management teams in navigating shifting international relationships.
As a member of the Financials sector and the Investment Banking & Brokerage sub-industry, PJT operates a fee-based advisory model in which revenue is typically driven by retainer and transaction-related fees tied to the size and completion of client engagements, rather than balance sheet exposure.
- M&A advisory revenue tracks global deal pipeline recovery
- Restructuring mandates rise amid corporate debt stress
- Compensation expense ratio remains key margin pressure
| Net Income: 199.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.38 > 0.02 and ΔFCF/TA 6.28 > 1.0 |
| NWC/Revenue: 28.46% < 20% (prev 31.41%; Δ -2.95% < -1%) |
| CFO/TA 0.41 > 3% & CFO 713.0m > Net Income 199.5m |
| Net Debt (183.8m) to EBITDA (429.3m): 0.43 < 3 |
| Current Ratio: 6.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.6m) vs 12m ago -34.10% < -2% |
| Gross Margin: 64.58% > 18% (prev 31.55%; Δ 33.04% > 0.5%) |
| Asset Turnover: 115.5% > 50% (prev 101.6%; Δ 13.93% > 0%) |
| Interest Coverage Ratio: 46.32 > 6 (EBIT TTM 405.1m / Interest Expense TTM 8.74m) |
| A: 0.31 (Total Current Assets 630.0m - Total Current Liabilities 93.0m) / Total Assets 1.76b |
| B: 0.27 (Retained Earnings 477.6m / Total Assets 1.76b) |
| C: 0.25 (EBIT TTM 405.1m / Avg Total Assets 1.63b) |
| D: 0.40 (Book Value of Equity 312.1m / Total Liabilities 772.6m) |
| Altman-Z'' = 4.98 = AAA |
| DSRI: 0.89 (Receivables 394.5m/359.0m, Revenue 1.89b/1.54b) |
| GMI: 0.49 (GM 31.55% / 64.58%) |
| AQI: 1.10 (AQ_t 0.40 / AQ_t-1 0.37) |
| SGI: 1.23 (Revenue 1.89b / 1.54b) |
| TATA: -0.29 (NI 199.5m - CFO 713.0m) / TA 1.76b) |
| Beneish M = -3.39 (Cap -4..+1) = AA |
As of August 22, 2026, the stock is trading at USD 174.96 with a total of 205,082 shares traded. Over the past week, the price has changed by +0.34%, over one month by +4.79%, over three months by +12.47% and over the past year by +0.43%.
Current recommended Stop Loss: 159.90 (which is 8.6% or 2.4 ATR below the current price).
PJT has received a consensus analysts rating of 2.67. Therefore, it is recommended to hold PJT.
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 187.8 | 7.3% |
P/E Trailing = 23.7548
P/E Forward = 22.3214
P/S = 3.9388
P/B = 14.6528
P/EG = 1.36
Revenue TTM = 1.89b USD
EBIT TTM = 405.1m USD
EBITDA TTM = 429.3m USD
Long Term Debt = 404.9m USD (estimated: total debt 419.4m - short term 14.5m)
Short Term Debt = 14.5m USD (from shortTermDebt, last quarter)
Debt = 419.4m USD (from shortLongTermDebtTotal, last quarter) (leases 419.4m already included)
Net Debt = 183.8m USD (calculated: Debt 419.4m - CCE 235.5m)
Enterprise Value = 7.61b USD (7.43b + Debt 419.4m - CCE 235.5m)
Interest Coverage Ratio = 46.32 (Ebit TTM 405.1m / Interest Expense TTM 8.74m)
EV/FCF = 11.50x (Enterprise Value 7.61b / FCF TTM 661.8m)
FCF Yield = 8.70% (FCF TTM 661.8m / Enterprise Value 7.61b)
FCF Margin = 35.08% (FCF TTM 661.8m / Revenue TTM 1.89b)
Net Margin = 10.58% (Net Income TTM 199.5m / Revenue TTM 1.89b)
Gross Margin = 64.58% ((Revenue TTM 1.89b - Cost of Revenue TTM 668.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.33 (Enterprise Value 7.61b / Total Assets 1.76b)
Interest Expense / Debt = 2.09% (Interest Expense 8.74m / Debt 419.4m)
Taxrate = 13.04% (51.7m / 396.3m)
NOPAT = 352.3m (EBIT 405.1m * (1 - 13.04%))
Current Ratio = 6.78 (Total Current Assets 630.0m / Total Current Liabilities 93.0m)
Debt / Equity = 1.34 (Debt 419.4m / totalStockholderEquity, last quarter 312.1m)
Debt / EBITDA = 0.43 (Net Debt 183.8m / EBITDA 429.3m)
Debt / FCF = 0.28 (Net Debt 183.8m / FCF TTM 661.8m)
Total Stockholder Equity = 280.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.21% (Net Income 199.5m / Total Assets 1.76b)
RoE = 71.16% (Net Income TTM 199.5m / Total Stockholder Equity 280.4m)
RoCE = 59.11% (EBIT 405.1m / Capital Employed (Equity 280.4m + L.T.Debt 404.9m))
RoIC = 22.25% (NOPAT 352.3m / Invested Capital 1.58b)
WACC = 10.20% (E(7.43b)/V(7.85b) * Re(10.67%) + D(419.4m)/V(7.85b) * Rd(2.09%) * (1-Tc(0.13)))
Discount Rate = 10.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -50.59 | Cagr: 0.72%
[DCF] Terminal Value 72.23% ; FCFF base≈587.0m ; Y1≈672.9m ; Y5≈990.4m
[DCF] Fair Price = 432.3 (EV 11.2b - Net Debt 183.8m = Equity 11.1b / Shares 25.6m; r=10.20% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.93 | EPS CAGR: 40.87% | SUE: 1.14 | # QB: 1
Revenue Correlation: 99.23 | Revenue CAGR: 20.91% | SUE: 1.47 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.87 | Chg30d=+3.29% | Revisions=-12% | Analysts=7
EPS current Year (2026-12-31): EPS=7.99 | Chg30d=+7.10% | Revisions=-29% | GrowthEPS=+14.5% | GrowthRev=+13.9%
EPS next Year (2027-12-31): EPS=9.07 | Chg30d=+5.56% | Revisions=+12% | GrowthEPS=+13.4% | GrowthRev=+11.3%
[Analyst] Revisions Ratio: -12% (up=6, down=8)